ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 807.9 USD | +0.05% |
|
+0.58% | +38.59% |
| May. 28 | Annual sales of weight-loss drugs seen hitting $150 billion | RE |
| May. 28 | Weight-loss drug forecasts jump to $150 billion as supply grows | RE |
Financials (USD)
| Sales 2024 * | 43B | Sales 2025 * | 52.61B | Capitalization | 727B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B | Net income 2025 * | 16.55B | EV / Sales 2024 * | 17.4 x |
| Net Debt 2024 * | 19.98B | Net Debt 2025 * | 15.29B | EV / Sales 2025 * | 14.1 x |
| P/E ratio 2024 * |
60.4
x | P/E ratio 2025 * |
43.5
x | Employees | 43,000 |
| Yield 2024 * |
0.64% | Yield 2025 * |
0.74% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.08% | ||
| 1 week | +0.58% | ||
| Current month | +3.43% | ||
| 1 month | +10.14% | ||
| 3 months | +6.63% | ||
| 6 months | +36.56% | ||
| Current year | +38.59% |
1 week
788.25
820.61
1 month
730.34820.61
Current year
579.05820.61
1 year
422.06820.61
3 years
196.68820.61
5 years
101.36820.61
10 years
58.50820.61
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 17 M€ | +7.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 807.9 | +0.05% | 2,483,454 |
| 24-05-24 | 807.4 | -0.13% | 1,778,120 |
| 24-05-23 | 808.4 | +0.69% | 3,025,781 |
| 24-05-22 | 802.9 | -0.03% | 1,767,519 |
| 24-05-21 | 803.2 | +2.55% | 4,334,499 |
Delayed Quote Nyse, May 28, 2024 at 04:00 pm EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +13.47% | 238B | |
| +7.35% | 204B | |
| -6.42% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B | |
| -1.31% | 120B |
- Stock Market
- Equities
- LLY Stock
